Hanall, “We received USD 30 million upfront payment for technology export from Roivant”

Published: 2017-12-28 16:28:45

Updated: 2017-12-28 16:28:45

Hanall Biohparma(CEO Seung-Gook Park, Jae-Choon Yoon) announced “We received the USD 30 million(approx. KRW 32.4 billion) upfront payment for its autoimmune disease antibody(HL161) technology agreement from Roivant Sciences on 26 December.”

Hanall Biopharma has signed a global technology export agreement of its autoimmune disease antibody(HL161) with Roivant Sciences on 19 December. The total ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.